Congratulations you’ve now reached the end of part 3. Well done!
In this part of the course, you have:
- Gotten an insight into the nearly empty pipeline of new antibiotics
- Reflected upon alternatives to antibiotics and carried out a quiz about antibiotic innovation
- Been provided study questions and an analytical assignment that aimed to anchor your acquired knowledge and stimulate reflection upon the access-excess dilemma.
- Learnt about the need for new business models addressing antibiotic resistance
- Discussed the dilemma of access and excess to antibiotics in low- and middle-income countries as well reflected upon who’s responsible for the fair distribution of antibiotics
In the next part, you’ll learn more about:
- Challenges to antibiotic resistance
- The future of antibiotics and resistance
- Ongoing initiatives to fight antibiotic resistance
- What we can do as individuals to tackle antibiotic resistance
© Uppsala University
More from "Part 3"
- Nearly empty pipeline
- Why don’t we simply develop new antibiotics?
- Alternatives to antibiotics
- New business models addressing antibiotic resistance
- How can we tackle this rather critical situation?
- Innovation of antibiotics
- Securing access while reducing excess
- Access not excess – rational use of antibiotics
- Who is responsible?
- Test your understanding III
- Reflection and analysis: the access-excess dilemma
- End of part 3